Amaryl Related Published Studies
Well-designed clinical trials related to Amaryl (Glimepiride)
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin
resistance in type 2 diabetic patients. [2014]
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2
diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results
from a randomised, double-blind, phase 3 non-inferiority trial. [2013]
[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate
glycaemic control with glimepiride]. [Article in German] [2013]
Efficacy and safety of glimepiride/metformin sustained release once daily vs.
glimepiride/metformin twice daily in patients with type 2 diabetes. [2013]
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. [2011.10]
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. [2011.09]
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. [2011.06]
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. [2011.04]
Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naive type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. [2011.02]
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. [2011.02]
Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes. [2011.02]
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). [2011.01]
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. [2011.01]
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate
glycaemic control with glimepiride: a randomized, 24-week, double-blind,
placebo-controlled trial. [2011]
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. [2010.09]
[Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)]. [2010.09]
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. [2010.09]
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. [2010.09]
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. [2010.08]
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. [2010.07]
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. [2010.07]
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. [2010.04]
Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. [2009.11]
A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. [2009.11]
Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. [2009.11]
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. [2009.07]
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. [2009.02.07]
Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. [2009]
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). [2008.10.17]
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. [2008.09]
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. [2008.04.02]
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. [2007.11]
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. [2006.12.06]
Bioequivalence assessment of the two brands of glimepiride tablets. [2006.12]
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. [2006.10]
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. [2006.05]
Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. [2006.05]
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. [2006.04]
Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. [2006.03]
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. [2006.03]
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. [2006.02]
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. [2006.01]
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. [2005.11]
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. [2005.08]
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. [2005.07]
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. [2005.06]
Efficacy of glimepiride in Japanese type 2 diabetic subjects. [2005.06]
Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. [2005.05]
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. [2005.05]
Bioequivalence evaluation of two brands of glimepiride 4 mg tablets in healthy subjects. [2005.04]
Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. [2004.11]
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. [2004.08]
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. [2004.06]
Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. [2004.06]
[Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy] [2004.05]
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. [2004.05]
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. [2004.05]
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. [2004.02]
Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. [2003.12]
Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. [2003.08]
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. [2003.06.17]
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study. [2003.06]
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. [2003.02]
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. [2003.02]
Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. [2003.01]
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. [2002.02]
The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. [2001.12]
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. [2001.11]
Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. [2001.10]
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. [2001.04]
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. [2000.12]
Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries. [2000.08]
Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. [1999.03]
Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man. [1999]
Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. [1998.11]
A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. [1998.07]
Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. [1998.07]
Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. [1997.07]
Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. [1997.06]
Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. [1996.11]
The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. [1996.09]
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. [1996.09]
Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. [1996.09]
Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. [1996.09]
A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. [1996.08]
Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. [1996]
Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. [1994]
Absolute bioavailability of glimepiride (Amaryl) after oral administration. [1994]
Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. [1993.08]
Well-designed clinical trials possibly related to Amaryl (Glimepiride)
Pioglitazone-mediated changes in lipoprotein particle composition are predicted
by changes in adiponectin level in type 2 diabetes. [2012]
Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. [2011.10]
Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). [2011.09]
Review of the therapeutic uses of liraglutide. [2011.07]
Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia. [2011.04]
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. [2011.01.11]
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. [2010.12]
Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes. [2010.12]
Vildagliptin: a review of its use in type 2 diabetes mellitus. [2010.11.12]
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study. [2010.08]
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus. [2010.07.09]
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes. [2010.07]
|
